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Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase
inhibitors are promising new drugs. The aim of this study was to determine the expression of EGF-receptor, Her-2/neu, and c-Kit
tyrosine kinases in CUP. Paraffin-embedded specimens were obtained from 54 patients with a CUP who were included in the
GEFCAPI 01 randomised phase II trial. Immunohistochemistry was performed using the Dako autostainer with antibodies directed
against HER-2/neu protein, EGFR protein, and c-Kit protein (CD117). EGFR expression was found in 36 out of 54 samples (66%). In
contrast, Her-2/neu overexpression and c-Kit positivity were only detected in 4 and 10% of patients, respectively. No significant
association was found between the expression of the tyrosine kinase receptors and prognosis. EGFR expression was significantly
associated with response to cisplatin-based chemotherapy: the response rates were 50 and 22% in patients with EGFR-positive
tumours and EGFR-negative tumours, respectively (Po0.05). This study shows that EGFR is frequently expressed in CUP. This finding
may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression
occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity.
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Carcinoma of an unknown primary site (CUP) rank among the 10
most frequent cancers worldwide and its prognosis is notoriously
poor with median survival rates attaining 8 months (Pavlidis and
Fizazi, 2005). Carcinoma of an unknown primary site are
heterogeneous tumours whose origin is unidentifiable at the time
of the diagnosis but they share the unique clinical feature of
metastatic disease: a slow local development and a high metastatic
potential. Despite advances in tumour imaging and pathology,
patients with CUP still account for about 5% of all cancer patients.
The primary site remains frequently unknown but necroptic
studies indicate that the primary sites are most often the pancreas,
lung, gut, and kidney.
The treatment of patients presenting with a CUP remains a daily
challenge for physicians. Although systemic chemotherapy is
usually recommended, the optimal regimen remains to be
determined. To improve the poor outcome of patients, several
recent studies have focused on the introduction of new cytotoxic
agents such as gemcitabine (GC), irinotecan (IC), and taxanes
which exhibit a broad spectrum of clinical activity (Greco et al,
2002; Culine et al, 2003). However, no randomised trial has
provided a clear evidence of a survival benefit for CUP patients
(Fizazi, 2006).
In addition, the biology of CUP is still very poorly understood
(Fizazi, 2006). Growth factor receptors with tyrosine kinase
activities such as EGFR, HER-2/neu, and c-Kit have recently
emerged as promising targets for novel therapeutic agents,
especially in some poorly chemosensitive neoplasms (Krause and
Van Etten, 2005). This prompted us to study receptor tyrosine
kinases, which could be potential targets for novel therapies in
patients with CUP.
We therefore studied tumour specimens from 54 patients with
CUP enrolled in one of a large prospective randomised phase II
trial (Culine et al, 2003) to determine EGFR, Her-2/neu, and c-Kit
protein expression.
MATERIALS AND METHODS
Patients
Tissues were obtained from the original biopsy specimens of 54
patients who were enrolled in a randomised phase II trial
(GEFCAPI 01) conducted by the French Study Group of
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November 2000 (Culine et al, 2003). The study was approved by
the Ethics Committee in Montpellier. All patients signed a written
informed consent before participation. Patients were randomly
assigned to one of the two treatment regimens at the time of study
entry and could receive chemotherapy combinations including
cisplatin with GC or IC. Patients were excluded if they had any of
the following features: a CUP subset requiring specific treatment
(i.e. women with adenocarcinoma with axillary lymph node
involvement alone, women with papillary serous carcinoma of
the peritoneum, patients with squamous carcinoma exclusively
involving cervical or inguinal lymph nodes, carcinomas with
neuroendocrine features, and patients with carcinoma in a
potentially resectable site) and those with symptomatic brain
metastasis. To exclude other malignancies (lymphoma, melanoma,
sarcoma, and neuroendocrine carcinoma), immunoperoxidase
staining with antibodies against leukocyte common antigen,
cytokeratin, neuroendocrine markers (chromogranin and
synaptophysin), and melanoma markers (S-100 protein and
homatropine methylbromide-45) was recommended in poorly
differentiated carcinoma. All specimens were centrally reviewed by
a single pathologist (JJV). Well-differentiated adenocarcinoma was
the most common histologic type. The dominant visceral sites of
disease were the bone, lung, and liver, whereas the mediastinum
was the most common site of lymph node involvement. The results
of this clinical trial have already been published (Culine et al,
2003). The study demonstrated the activity of both regimens in
CUP patients. Response to chemotherapy we evaluated by CT scan
after every two cycle of chemotherapy and independent radiologic
review was carried out. Moreover, a simple prognostic model was
established with Performans Status and LDH serum in CUP
patients (Culine et al, 2002).
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were immunostained
for EGFR, HER-2/neu, and c-Kit. Five-micrometer sections were
cut, deparaffinised, and rehydrated. There is no SOP (Standardized
Operation Procedures) for tissue collection. The slides were
processed using an autostainer (Dako, Carpinteria, CA, USA) with
a streptavidin–biotin complex and diaminobenzidine as the
chromogens. The antibodies used were the PharmDx EGFR kit
(Dako), the polyclonal rabbit anti-human-c-Kit (CD117, an epitope
of KIT) (A4502, Dako) (dilution 1:50) and the polyclonal rabbit
anti-human HER-2/neu – c-erbB-2 (A0485, Dako) (dilution
1:1500) in one slide for each antibody.
Microwave oven antigen retrieval from tissue sections was only
performed for HER-2/neu. For EGFR staining, tissue sections were
digested with protease K at 211C for 5min. Nonspecific binding
sites were bound using Protein Block (Dako). The slides were
incubated with primary antibody for 60min (HER-2/neu and
c-Kit) and 30min for EGFR. Staining was revealed using the
following chromogens: biotinylate secondary antibody, peroxi-
dase-labelled streptavidin and 3,30-diaminobenzidine tetra-
hydrochloride-hydrogen peroxide.
Dilution and incubation periods were optimised for each
antibody by using positive controls. Specimens whose incubation
with the primary antibody had been omitted were used as a
negative control. In each experiment, tumours with defined
alterations in EGFR, HER-2/neu, or c-Kit were used as positive
controls. Each case was scored by a pathologist blinded to patient
identity, and scoring system for EGFR, Her2/neu and Kit is based
on College of American Pathologists Cell Markers Committee
guidelines (Arch Pathol Lab Med 2002–2006).
EGFR positivity revealed by chromogenic staining was localised
mainly in the cell membrane. Three staining categories were
defined before assessing EGFR: specimens with no or less than 1%
of positive cells were defined as ‘negative’, specimens with 1–20%
of positive cells were defined as ‘positive þþ’ and specimens
with more than 20% of positive cells were defined as ‘positive
þþþ’. These definitions of positive and negative results are in
accordance with the published literature (Goldstein and Armin,
2001) but may require modification in specific context.
HER-2/neu expression was confirmed when staining was
localised in the membrane. Specimens were scored as 0 (no
staining or less than 10% of positive cells), 1þ (weak and focal
staining of more than 10% of positive cells), 2þ(weak to moderate
and complete membrane staining of more than 10% of positive
cells), and 3þ (strong and complete membrane staining of more
than 10% of positive cells). Specimens scored as 3þ are Her-2/neu
overexpression.
C-Kit expression was scored as negative when there was no
staining for c-Kit or when staining was observed in less than 1%
of the cells and as positive when the cytoplasm was strongly
stained with or without membrane staining in 10% or more cancer
cells. C-Kit expression was controlled with mast cells known to
express c-Kit.
Statistical analysis
Fischer’s exact test was used to evaluate differences in clinical
characteristics between positive and negative EGFR, Her-2/neu,
and c-Kit expression.
The following variables were studied: age, sex, pathology review,
ECOG, serum LDH, disease site, chemotherapy, and response to
chemotherapy. Differences in survival duration between subgroups
were analysed using a two-sided log rank.
All P-values were two-sided. Po0.05 was considered statistically
significant. All analyses were carried out with the SPSS package
(SPSS program stat).
RESULTS
Fourteen centres enrolled 80 patients onto the GEFCAPI 01 trial. A
pathological review of 75 specimens was performed. Tissue from
the original biopsy specimens was available in 54 patients for the
present immunohistochemical analysis. Patient characteristics are
summarised in Table 1.
Eighteen (33%) cases showed no EGFR expression. EGFR was
expressed in 36 (66%) of 54 available samples, displaying moderate
staining in 17 (31%) cases and strong EGFR positivity in 19 (35%) cases.
In the univariate analysis, EGFR expression correlated with
response to chemotherapy (Table 2), but not with age, gender,
tumour site, and pathological differentiation. Response to
cisplatin-based chemotherapy was 50 and 22% in patients with
EGFR-positive and -negative tumours respectively (P¼0.046).
Her-2 overexpression was found in only 2 (4%) of 54 tumour
specimens. There was no statistically significant correlation
between Her-2/neu staining and clinical characteristics, as
summarised in Table 1.
Only six cases (10%) showed at least some c-Kit expression.
There was no statistically significant correlation between c-Kit
staining and clinical characteristics, as summarised in Table 1.
DISCUSSION
In the present study, we showed that EGFR is expressed in a
majority (66%) of CUP. Moreover, EGFR expression correlated
with response to cisplatin-based chemotherapy. This study is
relatively small but it is one of the largest randomised trials in
CUP. Treating patients with CUP remains a challenge for
physicians and a better understanding of the biology of this
neoplasm with the identification of reliable tumour markers that
reflect tumour aggressiveness or of predictive factors for new
therapeutics might lead to targeted therapies. Growth factor
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promising targets for novel therapeutic agents in malignancies
such as lung cancer (Shepherd et al, 2005), breast cancer (Slamon
et al, 2001), and gastrointestinal stromal tumour (GIST) (Heinrich
et al, 2002). This study provides evidence for tyrosine kinase
receptor expression/lack of expression in CUP and may allow the
study of targeted therapies in these patients. Moreover, immuno-
histochemistry is an indispensable tool in diagnosis and manage-
ment of CUPs. The role of pathologist is to determine the
histopathological type rather than the origin of the primary
tumour in view of a suitable therapy based on clinical,
morphological, and phenotypic data (Fizazi, 2006).
In the last decade, EGFR has emerged as one of the most
important targets for drug development in oncology. Because
EGFR is expressed and associated with poor prognosis and a more
malignant phenotype in many neoplasms, it has been investigated
as a potential target for cancer therapy (Baselga and Arteaga, 2005;
Mendelsohn and Baselga, 2006). There are currently two treatment
options using anti-EGFR agents under clinical development: a
monoclonal antibody directed at the extracellular domain of the
receptor and small molecule inhibitors of the EGFR tyrosine
kinase. Clinical trials with a humanised murine chimeric mono-
clonal antibody to EGFR (C225, Cetuximab) in combination with
chemotherapy or radiotherapy have shown significant clinical
activity in advanced colorectal carcinomas (Cunningham et al,
2004) squamous cell carcinomas of the head and neck (Vermorken
et al, 2007), and non-small cell lung cancer (NSCLC) (Janne et al,
2004; Giaccone, 2005). On the other hand, a large number of
inhibitors of the EGFR tyrosine kinase are active against NSCLC
(Thatcher et al, 2005) and pancreatic cancer. It is well known that
lung cancer is one of the most frequent origin of unknown primary
cancer (Fizazi, 2006). The BR.21 study evaluated the effectiveness
Table 1 Clinical and pathological characteristics of patients with and without Her-2/neu overexpression, c-Kit expression and EGFR expression
Characteristics
All patients
(n¼54)
EGFR 
(n¼18)
EGFR+
(n¼36)
HER2/neu 
(n¼52)
HER2/neu+
(n¼2)
c-KIT 
(n¼48)
c-KIT+
(n¼6)
Age (years)
Median 58 58 55.5 58 52 55.5 66.5
Range 33–73 33–68 41–73 33–73 45–59 33–73 48–71
Sex
Male 31 (57%) 10 (55%) 21 (58%) 29 (56%) 2 (100%) 29 (60%) 2 (33%)
Female 23 (43%) 8 (45%) 15 (42%) 23 (44%) 0 19 (40%) 4 (67%)
Pathology
Adenocarcinoma 29 (53%) 10 (55%) 19 (53%) 27 (52%) 2 (100%) 27 (56%) 2 (33%)
Poorlydifferentiated 18 (33%) 7 (38%) 11 (30%) 18 (35%) 0 16 (33%) 2 (33%)
Undifferentiated 7 (13%) 1 (5%) 6 (17%) 7 (13%) 0 5 (11%) 2 (33%)
Treatment
1 28 (51%) 7 (38%) 21 (58%) 27 (52%) 1 (50%) 27 (56%) 1 (17%)
2 26 (49%) 11 (62%) 15 (42%) 25 (48%) 1 (50%) 21 (44%) 5 (83%)
Serum LDH
Normal 26 (48%) 9 (50%) 17 (47%) 26 (50%) 0 23 (48%) 3 (50%)
Elevated 22 (40%) 8 (45%) 14 (39%) 21 (40%) 1 19 (40%) 3 (50%)
Not available 6 (12%) 1 (5%) 5 (14%) 5 1 6 0
ECOG PS
0 43 (79.5%) 14 (78%) 29 (80%) 41 (79%) 2 38 (79%) 5 (83%)
1 10 (18.5%) 4 (22%) 6 (17%) 10 (19%) 0 9 (19%) 1 (17%)
Not available 1 1 1 0 1 0
Tumour site
Lymph nodes 32 (60%) 10 (55%) 25 (70%) 35 (67%) 2 (100%) 36 (75%) 4 (66%)
Liver 27 (50%) 11 (60%) 16 (44%) 27 (52%) 0 25 (52%) 2 (33%)
Lung 28 (52%) 11 (60%) 17 (47%1 26 (50%) 2 (100%) 26 (54%) 2 (33%)
Bone 19 (35%) 9 (50%) 10 (28%) 18 (35%) 1 (50%) 18 (37%) 0
Peritoneum 3 (5%) 3 (16%) 9 (25%) 3 (6%) 0 3 (6%) 0
Adrenal gland 6 (11%) 1 (5%) 5 (14%) 12 (23%) 0 6 (12%) 0
Pleura 4 (7%) 1 (5%) 3 (8%) 4 (8%) 0 4 (8%) 0
Brain 2 (4%) 0 2 (5%) 2 (4%) 0 1 (2%) 1 (17%)
Cutaneous 1 (2%) 0 1 (2.5%) 1 (2%) 0 1 (2%) 0
Others 10 (18%) 4 (22%) 6 (17%) 10 (19%) 0 10 (21%) 0
EGFR-negative tumour patient: EGFR score 1+. EGFR-positive tumour patient: EGFR score 2+ or 3+. Treatment 1: cisplatin and gemcitabin. Treatment 2: cisplatin and irinotecan.
Table 2 EGFR expression and response to chemotherapy
Response
EGFR
negative
(n¼18)
EGFR
positive
(n¼36) P-value
Complete response 0 1 (3%)
Partial response 4 (22%) 17 (47%)
Stable disease 5 (28%) 9 (25%)
Progressive disease 7 (39%) 5 (14%)
Not evaluable 2 (1%) 4 (11%)
Objective response rate 4 (22%) 18 (50%) o0.05
EGFR-negative tumour patient: EGFR score 1+. EGFR-positive tumour patient: EGFR
score 2+ or 3+.
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BR.21 study demonstrated that erlotinib has the potential to
improve overall survival to unselected chemotherapy refractory
NSCLC patients (Shepherd et al, 2005). A subset of NSCLS patients
achieve impressive responses with TKI. Several authors have
showed that the mutation or amplification of EGFR are associated
with dramatic and sustained response to TKI in lung cancer
(Taron et al, 2005; Tsao et al, 2005; Shigematsu and Gazdar, 2006).
Compounds such as cetuximab, gefitinib, and erlotinib could
prove valid for targeting tumours expressing EGFR in patients
selected according to this marker and may represent a novel
therapeutic strategy in patients with CUP (Sequist et al, 2007).
There is a need for strategies with anti-EGFR agents alone or in
combination with conventional chemotherapies and to explore
combinations with other molecularly targeted therapies such as
angiogenesis inhibitors. These new therapeutic approaches may
represent an exciting and promising way of improving the
unfavourable prognosis in CUP patients.
Response to cisplatin-based chemotherapy was better in patients
with EGFR-positive as compared to those with EGFR-negative
tumours whereas there is no difference in overall survival. Several
studies suggest that while gefitinib or erlotinib are not effective in
the general NSCLC population (Shepherd et al, 2005), these targeted
therapies have activity in selected patients, and never-smokers and
patients of Asian origin and women with adenocarcinoma might
expect improvement in survival (Brown and Shepherd, 2005).
Moreover, EGFR mutation or EGFR expression may be a positive
prognostic factor for survival in advanced NSCLC patients treated
with chemotherapy with or without erlotinib, and may predict
greater likelihood of response to chemotherapy with or without
erlotinib. However, our results must be viewed cautiously since the
number of patients was relatively small.
A study by Hainsworth et al (2000) showed that 11% of tumour
specimens overexpressed Her-2/neu using the Dako immuno-
histochemical method in a large group of patients who had
received uniform treatment with cisplatin-based chemotherapy. In
that study, Her-2/neu overexpression occurred mainly in patients
with poorly differentiated carcinoma or patients whose tumour
was predominantly located above the diaphragm, in the medias-
tinum or lungs. Another study demonstrated that patients with
CUP have a high overexpression of Her-2/neu (Pavlidis et al,
1995). In our study, Her-2/neu overexpression was observed in 4%
of tumour specimens but 60% of patients had adenocarcinoma and
only 30% patients had poorly undifferentiated adenocarcinoma
and undifferentiated carcinoma. In these studies, the difference in
Her-2/neu overexpression could be explained by the patient
population (poorly differentiated vs well-differentiated carcino-
ma). Moreover, it might be useful to standardise staining
procedures used or to compare Her-2/neu overexpression with
an immunohistochemical test and FISH amplification.
C-Kit is a tyrosine kinase receptor, which is a target for imatinib
mesylate (Gleevec; Novartis Pharma, Basel, Switzerland). Imatinib
therapy of c-Kit-positive tumours is an example of rationally
targeted cancer therapy, like trastuzumab for the treatment of Her-
2/neu-positive breast cancer. Certain malignancies such as chronic
myeloid leukaemia (O’Hare et al, 2006) and GISTs (Joensuu et al,
2002) express c-Kit and respond favourably to imatinib therapy. In
a recent study (Went et al, 2004), c-Kit expression was shown to
occur infrequently in most tumour types. In our study, only 11% of
CUP expressed c-Kit, and its expression was not correlated with
any clinical patient characteristics.
Anti-EGFR agents may be evaluated in patients with CUP, which
overexpress EGFR immunohistochemically. It would be interesting
to also study EGFR mutations and EGFR amplification in tumour
samples from these patients. Tumour tissues from GEFCAPI 01
are not available to study other molecular markers such as
Her-2 amplification, c-Kit mutations, or EGFR mutations or
amplification. This analysis could be performed on another
EGFR
Figure 1 Immunohistochemical patterns of EGFR expression in a
carcinomas of an unknown primary site (CUP) specimen showing strong
EGFR immunostaining (magnification  400).
HER-2
Figure 2 Immunohistochemical patterns of Her-2/neu expression in a
carcinomas of an unknown primary site (CUP) specimen showing strong
HER-2/neu immunostaining (magnification  400).
CD117
Figure 3 Immunohistochemical patterns of c-Kit expression in a
carcinomas of an unknown primary site (CUP) specimen showing strong
c-Kit immunostaining (magnification  400).
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targeted therapies. In particular, in lung cancer EGFR mutations or
EGFR amplification could predict response to EGFR tyrosine
kinases inhibitors (Shigematsu and Gazdar, 2006). Anti-EGFR
agents may be evaluated in second- or first-line therapy, in
combination with chemotherapy or alone (Figures 1–3).
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